A pharmaceutical composition of levamlodipine or a pharmaceutically acceptable salt thereof and a .beta. receptor blocking agent and a use thereof are provided. An active ingredient of the pharmaceutical composition contains levamlodipine or a pharmaceutically acceptable salt thereof and a .beta. receptor blocking agent in which the .beta. receptor blocking agent is one selected from nebivolol bisoprolol betaxolol celiprolol and nadolol. A use of the pharmaceutical composition in preparation of ...

A method for preparing levo-betaxolol hydrochloride is provided. The method includes using p-hydroxyl phenyl ethanol as starting material and obtaining the pure levo-betaxolol hydrochloride by selectively esterifying alcoholic hydroxyl, etherifying phenolic hydroxyl, aminating isopropyl amine and finally etherifying by cyclopropylmethanol and leading HCl to be salified. An important intermediate compound 2(2S)-3-(4-p-toluene sulfonyloxy ethyl phenoxy)-1,2-propylene oxide which is used for prepar...

The present invention describes an improved method for the preparation of l-[4-{2- (cyclopropylmethoxy)ethyl}phenoxy]-3-[(1-methylethyl)amino]-2-propanol of Formula-(I) and its pharmaceutically acceptable salt, which comprises reacting 4 - [ 2 - (Cyclopropylmethoxy) ethyl] phenol with epichlorohydrin in presence of mild base and polar protic solvent to isolate 1 - {4 - [2 - (cyclopropylmethoxy)ethyl] - phenoxy} - 2, 3 - epoxy propane, which is further reacted with isopropyl amine to get betaxolo...

La presente invencion se refiere al uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas por ejemplo de un los hemangiomas infantiles. El beta bloqueante puede ser un beta bloqueante no selectivo por ejemplo propranolol. La presente invencion proporciona una alternativa a los compuestos conocidos por ej. corticoides interferon o vincristina que se usan generalmente para el tratamiento de los hemangiomas. Reivindicacion 4: El uso de acuerdo con la...

The present invention relates to compositions and methods of treating human subjects with a beta-adrenergic receptor blocking agent (“beta-blocker”) provided in a time-sustained-release delivery system. The time-sustained-release drug delivery systems includes at least three populations of beads where each population of beads includes a beta-blocker. The beads may be selected from immediate-release beads enteric-release beads sustained-release beads and time-sustained-release beads. The beta-blo...